Aufrufe
vor 1 Jahr

Ein Manifest zur Veränderung

  • Weitere Details anzeigen
  • Diagnose
  • Cardiovascular
  • Global
  • Manifest
  • Politische
  • Zugang
  • Menschen
  • European
  • Erkennung
  • Risiko
  • Globalhearthub
  • Herz
  • Kreislauf
  • Herzkreislauf
  • Initiativeherzklappe
Entdecken Sie das wegweisende Manifest, das acht konkrete Handlungsempfehlungen zur Bekämpfung der weltweit häufigsten Todesursache bietet – von öffentlichen Aufklärungskampagnen bis zur Integration digitaler Technologien. Erfahren Sie, wie eine globale Initiative von Patientenorganisationen, Experten und politischen Akteuren frühe Diagnosen fördert und gesundheitliche Chancengleichheit stärkt. Ein Muss für alle, die Herzkreislauf-Prävention aktiv gestalten möchten! Hier gehts zum Impressum https://initiative-herzklappe.de/impressum

Früherkennung und

Früherkennung und Diagnose von Herz-Kreislauf-Erkrankungen: Ein Manifest für Veränderung Literaturverzeichnis 1. American Heart Association. nd. Atherosclerotic Cardiovascular Disease (ASCVD). Available from: https://www.heart.org/en/ professional/quality-improvement/ascvd [Accessed 29/02/2024] 2. British Heart Foundation. nd. Familial hypercholesterolaemia. Available from: https://www.bhf.org.uk/informationsupport/ conditions/familial-hypercholesterolaemia [Accessed 18/12/2023] 3. National Health System (NHS). nd. Overview: heart failure Available from: https://www.nhs.uk/conditions/heart-failure/ [Accessed 06/12/2023] 4. World Health Organization. 2021. Cardiovascular diseases (CVDs). Available from: https://www.who.int/news-room/factsheets/detail/cardiovascular-diseases-(cvds) [Accessed 27/11/2023] 5. Thiriet M. 2018. Cardiovascular Disease: An Introduction. Vasculopathies: Behavioral, Chemical, Environmental, and Genetic Factors. Berlin: Springer: 1-90 6. Roth G, Mensah G, Johnson C, et al. 2020. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. Journal of the American College of Cardiology 76(25): 2982-3021 7. United Nations Department of Economic and Social Affairs. 2012. Population ageing and the non-communicable diseases. New York: United Nations 8. World Health Organization, United Nations Development Programme. 2016. What ministries of labour and employment need to know. Gevena: World Health Organization and United Nations Development Programme 9. European Society of Cardiology. 2023. Price tag on cardiovascular disease in Europe higher than entire EU budget. Available from: https://www.escardio.org/The-ESC/Press-Office/Press-releases/Price-tag-on-cardiovascular-disease-in-Europehigher-than-entire-EU-budget [Accessed 13/02/2024] 10. Schweikert B, Hunger M, Meisinger C, et al. 2008. Quality of life several years after myocardial infarction: comparing the MONICA/KORA registry to the general population†. European Heart Journal 30(4): 436-43 11. Rad M, Ghanbari-Afra l, Hoseini M, et al. 2021. Effectiveness of self-care program on the quality of life in patients with coronary artery disease undergoing cardiac rehabilitation: A Randomized clinical trial. Journal of Education and Health Promotion 10: 10.4103/jehp.jehp_70_21 12. World Heart Federation. 2022. World Heart Vision 2030: Driving policy change. Geneva: World Heart Federation 13. LSE Consulting. 2023. Trends in avoidable mortality from cardiovascular disease in the European Union. London: LSE Consulting 14. Quinn G, Ranum D, Song E, et al. 2017. Missed Diagnosis of Cardiovascular Disease in Outpatient General Medicine: Insights from Malpractice Claims Data. The Joint Commission Journal on Quality and Patient Safety 43(10): 508-16 15. Fleming K, Horton S, Wilson M, et al. 2021. The Lancet Commission on diagnostics: transforming access to diagnostics. Lancet 398: 1997-2050 16. Public Health England. 2019. Health matters: preventing cardiovascular disease. Available from: https://www.gov.uk/ government/publications/health-matters-preventing-cardiovascular-disease/health-matters-preventing-cardiovasculardisease [Accessed 28/11/2023] 17. Bottle A, Kim D, Aylin P, et al. 2018. Routes to diagnosis of heart failure: observational study using linked data in England. Heart 104(7): 600-05 18. d’Arcy J, Coffey S, Loudon M, et al. 2016. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. European Heart Journal 37(47): 3515-22 19. Groenewegen A, Zwartkruis V, Rienstra M, et al. 2021. Improving early diagnosis of cardiovascular disease in patients with type 2 diabetes and COPD: protocol of the RED-CVD cluster randomised diagnostic trial. BMJ Open 11(10): 10.1136/ bmjopen-2020-046330 20. Freedman B, Hindricks G, Banerjee A, et al. 2021. World Heart Federation roadmap on atrial fibrillation - A 2020 update. Global Heart 16(1): 10.5334/gh.1023. 21. Ray K, Ference B, Séverin T, et al. 2022. World Heart Federation cholesterol roadmap 2022. Global Heart 17(1): 10.5334/gh.1154 22. Global Heart Hub. 2022. Cardio-diabetes think tank: Call to action. Galway: Global Heart Hub 23. Ferreira J, Kraus S, Mitchell S, et al. 2019. World Heart Federation roadmap for heart failure. Global Heart 14(3): 197-214 26

GLOBAL HEART HUB 24. Iyer P, Moreno G, Caneo L, et al. 2017. Management of late presentation congenital heart disease. Cardiology in the Young 27(S6): S31-S39 25. Banderali G, Capra M, Biasucci G, et al. 2022. Detecting Familial hypercholesterolemia in children and adolescents: potential and challenges. Italian Journal of Pediatrics 48: 10.1186/s13052-022-01257-y 26. Bedlington N, Abifadel M, Beger B, et al. 2022. The time is now: achieving FH paediatric screening across Europe - The Prague Declaration. GMS Health Innovation and Technologies 16: 10.3205/hta000136 27. MedTech Europe. 2021. An EU action plan for better cardiovascular health. Brussels: MedTech Europe 28. Hill N, Sandler B, Mokgokong R, et al. 2020. Cost-effectiveness of targeted screening for the identification of patients with atrial fibrillation: evaluation of a machine learning risk prediction algorithm. Journal of Medical Economics 23(4): 386-93 29. Bobrowska A, Seedat F. 2022. Updated definition of targeted screening will help clarify remit of expanded UK NSC. Available from: https://nationalscreening.blog.gov.uk/2022/05/26/updated-definition-of-targeted-screening-will-help-clarify-remitof-expanded-uk-nsc/ [Accessed 27/11/2023] 30. Marquina C, Morton J, Lloyd M, et al. 2024. Cost-effectiveness of screening strategies for familial hypercholesterolaemia: an updated systematic review. PharmacoEconomics: 10.1007/s40273-023-01347-7 31. European Alliance for Cardiovascular Health. 2022. A European cardiovascular health plan: The need and the ambition. Brussels: European Alliance for Cardiovascular Health 32. O’Kelly A, Michos E, Shufelt C, et al. 2022. Pregnancy and Reproductive Risk Factors for Cardiovascular Disease in Women. Circulation Research 130(4): 652-72 33. Wait S, Krishnaswamy P, Borregaard B, et al. 2020. Heart valve disease: working together to create a better patient journey. London: The Health Policy Partnership and the Global Heart Hub 34. Unite Annual Summit participant (anon). 2023. Statement made during expert workshop. Global Heart Hub Unite Annual Summit October, 2023; Barcelona 35. Pastore F, Parisi V, Romano R, et al. 2013. Genetic test for dilated and hypertrophic cardiomyopathies: useful or less than useful for patients? Translational medicine @ UniSa, 5: 14-7 36. Liao M, Wu C, Juang J, et al. 2021. Atrial fibrillation and the risk of sudden cardiac arrest in patients with hypertrophic cardiomyopathy - A nationwide cohort study. eClinicalMedicine 34: 10.1016/j.eclinm.2021.100802 37. Low Wang C, Hess C, Hiatt W, et al. 2016. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation 133(24): 2459-502 38. Almdal T, Scharling H, Jensen J, et al. 2004. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Archives of Internal Medicine 164(13): 1422-6 39. Gill J, Miracolo A, Politopoulou K, et al. 2024. How can we improve the secondary prevention of cardiovascular disease? London: London School of Economics 40. McCracken C, Raisi-Estabragh Z, Szabo L, et al. 2024. NHS Health Check attendance is associated with reduced multiorgan disease risk: a matched cohort study in the UK Biobank. BMC Medicine 22(1): 10.1186/s12916-023-03187-w 41. Morton J, Marquina C, Lloyd M, et al. 2023. Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost-Effectiveness Analysis. PharmacoEconomics 42(1): 91-107 42. ClinRisk. 2017. Welcome to the QRISK®3-2018 risk calculator Available from: https://www.qrisk.org/ [Accessed 13/02/2024] 43. National Health System. 2021. Annex A - Primary Care Networks - Plans for 2021/22 and 2022/23 - New PCN service requirements. Leeds: National Health System 44. Lingervelder D, Koffijberg H, Emery J, et al. 2022. How to Realize the Benefits of Point-of-Care Testing at the General Practice: A Comparison of Four High-Income Countries. International Journal of Health Policy and Management 11(10): 2248-60 45. Hasin T, Zalut T, Hasin Y. 2018. Managing the Patient with Heart Failure in the Emergency Department. European Heart Journal 39(38): 3493-95 46. British Heart Foundation. 2023. Numbers of heart patients waiting over four months at record high. Available from: https:// www.bhf.org.uk/what-we-do/news-from-the-bhf/news-archive/2023/april/numbers-of-heart-patients-waiting-over-fourmonths-at-record-high [Accessed 06/12/2023] 27

Bisher erschienene Podcasts

Copyright © 2026 GUT ZUM HERZ All rights reserved.